SNDX - NASDAQ

Syndax Pharmaceuticals, Inc.

SNDX·NASDAQ

$18.34

-2.7%

HealthcareBiotechnology

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.63B

EPS-3.2900

P/E Ratio-5.57

Earnings Date08/03/2026

sndx

Inventory

Last Annual Value

32.75M

3-Year CAGR

5-Year CAGR

10-Year CAGR

62%

Adjust for Inflation

Syndax Pharmaceuticals, Inc. Competitors Analysis of Inventory

SNDX · NASDAQ

Company	Inventory	CAGR 3Y	CAGR 5Y	CAGR 10Y
Syndax Pharmaceuticals, Inc. NASDAQ:SNDX	32.75M	N/A	N/A	29.8%
Zenas BioPharma, Inc. NASDAQ:ZBIO	0.00	N/A	N/A	N/A
Nektar Therapeutics NASDAQ:NKTR	0.00	N/A	N/A	N/A
ORIC Pharmaceuticals, Inc. NASDAQ:ORIC	0.00	N/A	N/A	N/A
Atai Beckley Inc. NASDAQ:ATAI	0.00	N/A	N/A	N/A
Inhibrx Biosciences, Inc. NASDAQ:INBX	0.00	N/A	N/A	N/A
Amylyx Pharmaceuticals, Inc. NASDAQ:AMLX	0.00	N/A	N/A	N/A
Sana Biotechnology, Inc. NASDAQ:SANA	0.00	N/A	N/A	N/A
Relay Therapeutics, Inc. NASDAQ:RLAY	0.00	N/A	N/A	N/A

Syndax Pharmaceuticals, Inc. Fair Value Envelope

SNDX · NASDAQ

Our analysis suggests that SNDX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $18.34, this represents a potential HIDDEN relative to our calculated worth for Syndax Pharmaceuticals, Inc..

HIDDEN

Intrinsic Value

Current Price: $18.34

Related Guides

Blog Categories

Continue your SNDX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.